PMID- 26108737
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20181202
IS  - 1532-2157 (Electronic)
IS  - 0748-7983 (Linking)
VI  - 41
IP  - 9
DP  - 2015 Sep
TI  - Contralateral lymph node recurrence in breast cancer: Regional event rather than 
      distant metastatic disease. A systematic review of the literature.
PG  - 1128-36
LID - S0748-7983(15)00473-4 [pii]
LID - 10.1016/j.ejso.2015.05.015 [doi]
AB  - AIMS: After treatment for breast cancer, some patients experience a contralateral 
      lymph node recurrence (CLNR). Traditionally, contralateral nodes are considered a 
      distant site. However, aberrant lymph drainage after previous surgery is common. 
      This might indicate that CLNR is a regional event. This study aimed to review the 
      literature to determine prognosis after CLNR. METHODS: PubMed was searched up 
      until July 2014. Articles on CLNR with or without ipsilateral breast tumour 
      recurrence (IBTR), and repeat sentinel node (SN) studies reporting on positive 
      contralateral nodes were included. Exclusion criteria were synchronous 
      contralateral breast cancer and synchronous distant events. RESULTS: 24 articles 
      were included, describing 48 patients. Of these 48, 26 patients had an isolated 
      CLNR, 7 IBTR and clinically detected CLNR, and 15 IBTR with a positive 
      contralateral repeat SN. Isolated CLNR occurred earlier (45.9 months) than IBTR 
      with CLNR (126.6 months, p < 0.001) or with a positive contralateral repeat SN 
      (217.2, p = 0.02). Surgical treatment was described for 38 patients, and 
      consisted of axillary lymph node dissection for 34 (89.5%). Information on 
      adjuvant therapy was available for 27 patients, 21 (77.8%) received chemotherapy. 
      Follow-up information after CLNR was available for 23 patients (47.9%). Mean 
      follow-up was 50.3 months. Overall survival and disease-free survival were 82.6% 
      [95% CI 67.1-98.1] and 65.2% [45.7-84.7] respectively at last follow-up. 
      CONCLUSIONS: Although observed in a small population, the survival of CLNR is not 
      comparable to distant disease. Most patients received locoregional and systemic 
      treatment suggesting a curative approach. This indicates that CLNR should be 
      regarded as a regional event.
CI  - Copyright (c) 2015 Elsevier Ltd. All rights reserved.
FAU - Moossdorff, M
AU  - Moossdorff M
AD  - Department of Surgery, Maastricht University Medical Center, Maastricht, The 
      Netherlands; GROW School for Oncology and Developmental Biology, Maastricht 
      University, Maastricht, The Netherlands. Electronic address: 
      martine.moossdorff@mumc.nl.
FAU - Vugts, G
AU  - Vugts G
AD  - Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands. Electronic 
      address: guusje.vugts@cze.nl.
FAU - Maaskant-Braat, A J G
AU  - Maaskant-Braat AJ
AD  - Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
FAU - Strobbe, L J A
AU  - Strobbe LJ
AD  - Department of Surgery, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
FAU - Voogd, A C
AU  - Voogd AC
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands; Department of Epidemiology, Maastricht University, 
      Maastricht, The Netherlands; Department of Research, Comprehensive Cancer Centre 
      The Netherlands, Eindhoven, The Netherlands.
FAU - Smidt, M L
AU  - Smidt ML
AD  - Department of Surgery, Maastricht University Medical Center, Maastricht, The 
      Netherlands; GROW School for Oncology and Developmental Biology, Maastricht 
      University, Maastricht, The Netherlands.
FAU - Nieuwenhuijzen, G A P
AU  - Nieuwenhuijzen GA
AD  - Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20150609
PL  - England
TA  - Eur J Surg Oncol
JT  - European journal of surgical oncology : the journal of the European Society of 
      Surgical Oncology and the British Association of Surgical Oncology
JID - 8504356
SB  - IM
MH  - Axilla
MH  - Breast Neoplasms/*pathology/therapy
MH  - Chemotherapy, Adjuvant
MH  - Female
MH  - Humans
MH  - *Lymph Node Excision
MH  - Lymph Nodes/*pathology
MH  - Lymphatic Metastasis
MH  - *Mastectomy
MH  - Neoplasm Recurrence, Local/*pathology
MH  - Prognosis
MH  - Radiotherapy, Adjuvant
OTO - NOTNLM
OT  - Breast cancer
OT  - Contralateral
OT  - Distant recurrence
OT  - Lymph nodes
OT  - Regional recurrence
EDAT- 2015/06/26 06:00
MHDA- 2015/10/27 06:00
CRDT- 2015/06/26 06:00
PHST- 2015/01/26 00:00 [received]
PHST- 2015/05/04 00:00 [revised]
PHST- 2015/05/27 00:00 [accepted]
PHST- 2015/06/26 06:00 [entrez]
PHST- 2015/06/26 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - S0748-7983(15)00473-4 [pii]
AID - 10.1016/j.ejso.2015.05.015 [doi]
PST - ppublish
SO  - Eur J Surg Oncol. 2015 Sep;41(9):1128-36. doi: 10.1016/j.ejso.2015.05.015. Epub 
      2015 Jun 9.